BSD Medicals China Distributor Orders Two BSD-2000 Hyperthermia Systems

BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that Dalian Orientech Co. Ltd (“Orientech”), the Company’s exclusive China distributor, has ordered two BSD-2000 Hyperthermia Systems (BSD-2000). The BSD-2000 System utilizes BSD’s proprietary synchronous phased array technology to non-invasively target therapeutic heating (hyperthermia) to certain cancerous tumors, including those located deep within the body. Clinical studies have shown that hyperthermia treatment can kill cancer cells directly as well as increase the effectiveness of other cancer therapies, including radiation therapy, for the treatment of certain tumors.

Hyperthermia cancer therapy has a strong following in China, and Orientech controls about 65% of the market. The Orientech sales force covers 23 provinces. After shipping the two systems, the Company will have sold 19 BSD-2000 Hyperthermia Systems to Orientech.

Bristol-Myers Squibb to Acquire ZymoGenetics

    * Builds on Long-standing Commitment to Virology
    * Gains Full Rights to Promising Phase II Hepatitis C Biologic, Pegylated-Interferon Lambda
    * Obtains FDA-Approved Specialty Surgical Biologic, RECOTHROM®
    * Attains Early Clinical and Pre-clinical Programs in Oncology and Immunoscience

Bristol-Myers Squibb Company (NYSE:BMY - News) and ZymoGenetics, Inc. (NASDAQ: ZGEN - News) announced today that the companies have signed a definitive agreement providing for the acquisition of ZymoGenetics by Bristol-Myers Squibb, for $9.75 per share in cash. The transaction, with an aggregate purchase price of approximately $885 million, or approximately $735 million net of cash acquired, has been unanimously approved by the boards of directors of both companies.

Rexahn Pharmaceuticals Submits Serdaxin Phase IIb Protocol to FDA for Major Depressive Disorder (MDD)

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

The Phase IIb study will assess Serdaxin’s efficacy as a treatment for major depressive disorder in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will be conducted at multiple sites in the U.S. and will measure the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary efficacy endpoint.

Point Roberts, WA (Investorideas.com Newswire) September 3, 2010- InvestorIdeas.com, leader in sector research for investors, reports on recent Healthcare Technology Stocks news and trading for September 3rd.

Healthcare Technology Stocks include Healthmed Services Ltd. (OTCBB: HEME), Cytta Corp. (OTCBB: CYCA), Healthstream Inc.  (NASDAQ:HSTM), A.D.A.M. Inc. (NGM: ADAM) and Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)

Sector Snapshot: Trading at time or release

Allscripts (NASDAQ:MDRX ) trading at $17.59 USD, up 0.25 (1.44%)

A.D.A.M. Inc. (NGM: ADAM) trading at $ 5.50, up 0.03 (0.55%)

Cytta Corp. (OTCBB: CYCA) trading at 0.0017 - 0.0018